pharmanewsdaily

Amylyx Pharmaceuticals said that the last enrolled patient in the CENTAUR clinical trial, which is evaluating AMX0035 for amyotrophic lateral sclerosis (ALS), has finished the 24 weeks of study treatment. The CENTAUR clinical study is a randomized, double-blind, placebo-controlled phase 2 clinical trial. The primary goals of the mid-stage clinical trial are to assess the […]

AstraZeneca has bagged approval from the US Food and Drug Administration (FDA) for the self-administration of FASENRA (benralizumab) through FASENRA Pen, a pre-filled, single-use auto-injector, for the add-on maintenance treatment of severe asthma in patients aged 12 years and older, and with an eosinophilic phenotype. FASENRA is a monoclonal antibody which directly binds to the […]

The post FDA approves AstraZeneca’s FASENRA self-administration via FASENRA Pen appeared first on PharmaNewsDaily.com.

Icosavax, a new pharma company, focused on developing vaccines against infectious diseases, has been launched in Seattle, Washington. The vaccine development company is backed by $51 million capital raised through a Series A financing round led by Qiming Venture Partners USA. Other investors in Icosavax are Sanofi Ventures, Adams Street Partners, and NanoDimension, alongside continuing […]

The post Icosavax, a new vaccine development company, launched in Seattle appeared first on PharmaNewsDaily.com.

Graybug Vision has initiated the ALTISSIMO clinical trial, a phase 2b study, which will evaluate its pan-VEGF receptor inhibitor GB-102 in patients with wet age-related macular degeneration (wet AMD). Based in California, Graybug Vision is a clinical-stage pharma company engaged in developing drugs for ocular diseases like wet AMD, diabetic macular edema (DME), primary open […]

The post Graybug Vision initiates ALTISSIMO clinical trial for GB-102 in wet AMD appeared first on PharmaNewsDaily.com.

US immuno-oncology company Elicio Therapeutics has raised $33 million through a Series B financing round to advance ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS), and other lymph node targeted immuno-therapies. Elicio Therapeutics said that it has established an international investor base which includes Clal Biotechnology Industries, Efung Capital, and Livzon Pharmaceutical Group. According to the […]

The post Elicio raises $33m to advance lymph node-targeted immuno-therapies appeared first on PharmaNewsDaily.com.

Checkmate Pharmaceuticals announced the dosing of the first patient in a phase 1b/2 study of BAVENCIO (avelumab) in multi-drug combinations with its lead candidate CMP-001 in patients having squamous cell cancer of the head and neck (SCCHN), as part of the JAVELIN Medley trial. CMP‐001 is a C0pG‐A Toll‐like receptor 9 (TLR9) agonist that is […]

The post JAVELIN Medley trial : First patient dosed with BAVENCIO, CMP-001 combo appeared first on PharmaNewsDaily.com.